Toll样受体在放化疗诱导的消化道黏膜炎中的作用

被引：4

作者：

嵇灵 ^{[1
]}

王甲河 ^{[1
]}

王建涛 ^{[2
]}

王艳 ^{[3
]}

机构：

[1] 口腔疾病研究国家重点实验室国家口腔疾病临床研究中心四川大学华西口腔医院

[2] 生物治疗国家重点实验室四川大学华西医院肺癌中心四川大学华西医院放疗中心

[3] 口腔疾病研究国家重点实验室国家口腔疾病临床研究中心四川大学华西口腔医院儿童口腔科

来源：

口腔疾病防治 | 2021年 / 29卷 / 02期

关键词：

Toll样受体; 口腔黏膜炎; 胃肠道黏膜炎; 化疗; 放疗; Toll样受体2; Toll样受体4; Toll样受体5; Toll样受体9;

D O I：

暂无

中图分类号：

R730.6 [肿瘤并发症]; R781.5 [口腔粘膜病];

学科分类号：

100120 [医学发育生物学]; 100201 [内科学];

摘要：

黏膜炎是肿瘤患者进行放化疗时常见的消化道并发症,包括口腔黏膜炎和胃肠道黏膜炎,临床表现为口腔溃疡、呕吐、腹泻和疼痛等症状,严重降低患者的生活质量,甚至影响抗癌治疗。Toll样受体(Toll-like receptor,TLR)是参与天然免疫的重要受体,通过介导微生物与宿主之间的作用参与放化疗诱导黏膜炎的发生发展。文本针对现有TLR与黏膜炎相关研究予以综述。文献复习结果表明,不同TLR在放化疗诱导的黏膜炎中作用不同:TLR2是放化疗诱导的黏膜炎发生中炎性级联反应的重要受体;TLR4的激活能增加胃肠道黏膜炎症反应以及导致口腔上皮溃疡形成;TLR5激动剂能够降低放疗诱导的黏膜炎损伤程度;拮抗或敲除TLR9可减轻放化疗诱导的胃肠道黏膜炎。然而,目前尚未有TLR相关激动剂或抑制剂应用于临床,未来需要更多的研究对不同TLR在黏膜炎中的作用进行探讨,为放化疗性黏膜炎的精准防治提供参考。

引用

页码：124 / 129

页数：6

共 17 条

[1]

放化疗性口腔黏膜炎动物模型研究进展 [J].

邹晓龙 ;

陈媛 ;

王艳 ;

王建涛 .

口腔疾病防治, 2020, 28 (05) :322-326

[2]

Importance of TLR9-IL23-IL17 axis in inflammatory bowel disease development: Gene expression profiling study.[J].Sanja Dragasevic;Biljana Stankovic;Aleksandra Sokic-Milutinovic;Tomica Milosavljevic;Tamara Milovanovic;Snezana Lukic;Sanja Srzentic Drazilov;Kristel Klaassen;Nikola Kotur;Sonja Pavlovic;Dragan Popovic.Clinical Immunology.2018,

[3]

NF-κB-iNOS-COX2-TNF α inflammatory signaling pathway plays an important role in methotrexate induced small intestinal injury in rats.[J].Kasthuri Natarajan;Premila Abraham;Rekha Kota;Bina Isaac.Food and Chemical Toxicology.2018,

[4]

Toll and Toll-like receptor signalling in development [J].

Anthoney, Niki ;

Foldi, Istvan ;

Hidalgo, Alicia .

DEVELOPMENT, 2018, 145 (09)

[5]

TLR9 activation suppresses inflammation in response to Helicobacter pylori infection [J].

Varga, Matthew G. ;

Piazuelo, M. Blanca ;

Romero-Gallo, Judith ;

Delgado, Alberto G. ;

Suarez, Giovanni ;

Whitaker, Morgan E. ;

Krishna, Uma S. ;

Patel, Rachna V. ;

Skaar, Eric P. ;

Wilson, Keith T. ;

Algood, Holly M. S. ;

Peek, Richard M., Jr. .

AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2016, 311 (05) :G852-G858

[6]

Pharmacotherapy for the management of cancer regimen-related oral mucositis [J].

Villa, Alessandro ;

Sonis, Stephen T. .

EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (13) :1801-1807

[7]

Toll-like receptors in the pathogenesis of chemotherapy-induced gastrointestinal toxicity.[J].Elke Cario.Current Opinion in Supportive and Palliative Care.2016,

[8]

TLR2, TLR4 and CD86 gene polymorphisms in recurrent aphthous stomatitis [J].

Karasneh, Jumana ;

Bani-Hani, Maisoun ;

Alkhateeb, Asem ;

Hassan, Ahmad ;

Alzoubi, Firas ;

Thornhill, Martin .

JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2015, 44 (10) :857-863

[9]

CBLB502; an agonist of Toll-like receptor 5; has antioxidant and scavenging free radicals activities in vitro.[J].Weiguang Li;Changhui Ge;Liu Yang;Ruixue Wang;Yiming Lu;Yan Gao;Zhihui Li;Yonghong Wu;Xiaofei Zheng;Zhaoyan Wang;Chenggang Zhang.International Journal of Biological Macromolecules.2016,

[10]

Chemotherapy-driven dysbiosis in the intestinal microbiome [J].

Montassier, E. ;

Gastinne, T. ;

Vangay, P. ;

Al-Ghalith, G. A. ;

des Varannes, S. Bruley ;

Massart, S. ;

Moreau, P. ;

Potel, G. ;

de La Cochetiere, M. F. ;

Batard, E. ;

Knights, D. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (05) :515-528

← 1 2 →